Cosmos Health Q3 2023: Revenue $12.8M (+7% YoY), net loss $3.35M, Adj. EBITDA -$1.1M

Cosmos Health Inc.

2023-Q3 EPS reported -$0.42 revenue$37,537,003

Revenue $12.8M (+7% YoY); gross margin declined to 9.5% from 14.9% due to logistics mix.
Net loss $3.35M vs $1.97M in Q3 2022; Adjusted EBITDA -$1.1M vs +$0.5M.
SG&A doubled to $4.0M on R&D, acquisition integration, stock-based comp, and provisions.
Total assets record $71.5M; stockholders' equity $44.2M ($3.4/share); debt reduced.
Reiterated 2026 guidance: >$180M revenue, >$20M EBITDA; plans to spin off R&D division.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Cosmos Health Inc. reported the third quarter and nine months ended September 30, 2023 results: revenue $12.8 million. Guidance reaffirmed.

Period: the third quarter and nine months ended September 30, 2023
Revenue: $12.8 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

a business update and reported financial results for the third quarter and nine months ended September 30, 2023. Third Quarter 2023 Financial Highlights · Revenues increased to $12.8 million from $12.0 million in Q3 2022, largely due to increased sales attributable to the logistics distribution business, which expanded following the acquisition of the Bikas GP

View on SEC.gov

Browse all earnings releases →

Cosmos Health Inc. filing history →

Source: SEC EDGAR

accession 0001477932-23-008752

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.